First-In-Human Trial of the MiStent Drug-Eluting Stent (DES) in Coronary Artery Disease (DESSOLVE-I)

Inclusion Criteria:

1. Male and female patients of age ≥18 years and ≤85 years;
2. Documented stable or unstable angina pectoris (Class I, II, III or IV), documented ischemia, or documented silent ischemia;
3. Planned single, de novo, types A, B1 and B2 coronary lesions (according to the ACC/AHA classification);
4. Target lesion located in a native coronary artery;
5. Target lesion in vessel with diameter ranging from 2.5 to 3.5 mm amenable to treatment (coverage) with a maximum 23 mm long stent;
6. Target lesion with >50% diameter stenosis;
7. Patients who are eligible for percutaneous coronary intervention (PCI);
8. Acceptable candidate for myocardial revascularization surgery (coronary artery bypass graft surgery);
9. A patient may have one additional critical non-target lesion. The target lesion is the only lesion that must meet the study inclusion requirements. The non-target lesion may be treated at the time of the index procedure but must be successfully treated without complications before the target lesion. The non-target lesion will not be considered to be part of the study and does not require the follow-up evaluations defined in the protocol. If more than one lesion meets the inclusion criteria, only one lesion/vessel chosen by the Investigator should be treated with the study stent; the other lesion(s) should be treated outside the study with approved devices;
10. The patient has been fully informed of the nature of the study, is willing to comply with all study requirements and will provide written informed consent as approved by the Ethics Committee of the respective clinical site.

Exclusion Criteria:

1. Female patients of childbearing potential who are not on some form of birth control with a confirmed negative pregnancy test at baseline;
2. Recent Q-wave myocardial infarction occurred within 72 hours prior to the index procedure. Recent Q-wave or non-Q-wave myocardial infarction with still elevated levels of cardiac markers (e.g. CK and CK-MB);
3. Documented left ventricular ejection fraction <30% at any time prior to study entry;
4. Patients in cardiogenic shock;
5. Cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months;
6. Active GI bleeding within past three months;
7. Any prior true anaphylactic reaction to contrast agents;
8. Patient is receiving or scheduled to receive chemotherapy within 30-days before or after the index procedure;
9. Patient is receiving oral or intravenous immunosuppressive therapy or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus);
10. Renal dysfunction (creatinine > 2.0 mg/dL or 177 µmol/L);
11. Platelet count <100,000 cells/mm³ or >700,000 cells/mm³;
12. White blood cell count <3,000 cells/mm3;
13. Suspected or documented hepatic disease (including laboratorial evidence of hepatitis);
14. Heart transplant recipient;
15. Known contraindication to dual antiplatelet therapy (DAPT);
16. Known hypersensitivity to sirolimus (or its structurally related compounds), cobalt-chromium, or to medications such as aspirin, heparin, and all three of the following: clopidogrel bisulfate (Plavix), ticlopidine (Ticlid), and Prasugrel (Effient);
17. Concurrent medical condition with a life expectancy of less than 12 months;
18. Any major medical condition that, in the Investigator's opinion, may interfere with the optimal participation of the patient in this study;
19. Patient is currently participating in an investigational drug or another device study and has not completed the follow-up to the primary endpoint, or the patient in planning on participating in an investigational drug or another device study during the course of the present investigation prior to completing 12-months follow-up;
20. Target vessel(s) has been treated within 10 mm proximal or distal to target lesion (by visual estimate) with any type of PCI (e.g., balloon angioplasty, stent, cutting balloon, atherectomy) within a year prior to index procedure;
21. Planned or actual target vessel(s) treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter prior to stent placement;
22. Patient previously treated at any time with coronary intravascular brachytherapy;
23. Planned coronary angioplasty (with or without stenting) or CABG in the first 9 months after the index procedure;
24. Prior PCI of a non-target vessel must be at least 30 days prior to study enrollment;
25. The intent to direct stent the target lesion;

26. Angiographic Exclusion Criteria: To be assessed at the time of the index procedure catheterization prior to stent placement;

    • In-stent restenotic target lesion;
    • More than one lesion requiring treatment in the target vessel (i.e. another lesion with >50% diameter stenosis (DS) proximal or distal to the target lesion);
    • Target vessel diameter <2.5 mm or >3.5 mm;
    • Long target lesion not amenable to treatment (coverage) with a 23 mm long stent;
    • Unprotected coronary artery branch lesion (≥50% DS);
    • Target lesion is located in a surgical bypass graft;
    • Total vessel occlusion (TIMI flow grade 0-1);
    • Target lesion with ostial location (within 5 mm of ostium by visual assessment);
    • Target lesion located in a lateral branch bifurcation >2.5mm or requiring lateral branch stenting;
    • Calcified target lesion that anticipates unsuccessful/impracticable predilation;
    • Target vessel with excessive tortuosity or proximal angulation (>90 degrees);
    • Thrombus present in target vessel;
    • More than one non-target critical lesion;

Non-target lesion to be treated during the index procedure meets any of the following criteria:

• Located within the target vessel;
• Located within a bypass graft (venous or arterial);
• Left main location;
• Chronic total occlusion;
• Involves a complex bifurcation (e.g., bifurcations requiring treatment with more than 1 stent).